Litigation Details for GENENTECH, INC. v. SANDOZ, INC. (D.N.J. 2017)

GENENTECH, INC. v. SANDOZ, INC. (D.N.J. 2017)

Docket		Date Filed	2017-12-21
Court	District Court, D. New Jersey	Date Terminated	2018-12-07
Cause	15:1126 Patent Infringement	Assigned To
Jury Demand	Both	Referred To
Patents	8,512,983; 8,574,869; 9,714,293
Link to Docket	External link to docket

Details for GENENTECH, INC. v. SANDOZ, INC. (D.N.J. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-12-21				External link to document

Genentech v. Sandoz, 1:17-cv-13507: Esbriet Patent Litigation Summary

Last updated: August 8, 2026

Genentech’s litigation against Sandoz in Genentech, Inc. v. Sandoz Inc., No. 1:17-cv-13507, U.S. District Court for the District of New Jersey, concerned Sandoz’s abbreviated new drug application for generic pirfenidone, the active ingredient in Genentech’s Esbriet product for idiopathic pulmonary fibrosis. Genentech asserted U.S. Patent No. 7,566,729 under the Hatch-Waxman Act after receiving Sandoz’s Paragraph IV certification. The district court held the asserted claims invalid for obviousness, and the Federal Circuit affirmed in 2022. The decision removed the principal patent barrier to Sandoz’s generic pirfenidone product.

What drug and product were at issue in Genentech v. Sandoz?

The case involved pirfenidone, marketed by Genentech as Esbriet.

Item	Details
Brand	Esbriet
Active ingredient	Pirfenidone
Sponsor	InterMune, later acquired by Roche/Genentech
FDA indication	Idiopathic pulmonary fibrosis
FDA approval	October 15, 2014
NDA	205832
Generic applicant	Sandoz Inc.
Regulatory pathway	ANDA
Court	U.S. District Court for the District of New Jersey
Case number	1:17-cv-13507
Primary asserted patent	U.S. Patent No. 7,566,729
Federal Circuit decision	Genentech, Inc. v. Sandoz Inc., 55 F.4th 1368 (Fed. Cir. 2022)

FDA approved Esbriet in 2014 for adults with idiopathic pulmonary fibrosis, a progressive fibrotic lung disease. The approved product included 267 mg capsules and 801 mg tablets. The commercial dosing regimen is titrated during the first two weeks before reaching a maintenance dose of 801 mg three times daily. [1]

What patents did Genentech assert against Sandoz?

Genentech’s principal claim in this action was based on U.S. Patent No. 7,566,729, which covered methods of treating idiopathic pulmonary fibrosis with pirfenidone.

The patent was directed to the therapeutic use of pirfenidone rather than to a new chemical compound. That distinction drove the litigation. Sandoz’s ANDA product contained the same active ingredient as Esbriet, so the dispute focused on whether the claimed treatment method was patentably distinct from the prior art.

U.S. Patent No. 7,566,729

The asserted patent claimed methods of treating idiopathic pulmonary fibrosis by administering pirfenidone at therapeutically effective amounts. Genentech argued that the prior art did not make the claimed treatment regimen obvious because pirfenidone’s clinical efficacy in IPF was uncertain before the relevant filing date.

Sandoz argued that the prior art disclosed pirfenidone, its antifibrotic properties, and its potential use in pulmonary fibrosis. The company maintained that a skilled person would have had a reason to investigate pirfenidone for IPF and a reasonable expectation of success.

The district court accepted Sandoz’s obviousness theory. The Federal Circuit affirmed.

When did Genentech sue Sandoz over generic pirfenidone?

Genentech filed the action in November 2017 after Sandoz notified Genentech of its Paragraph IV certification. The filing triggered Hatch-Waxman patent litigation under 35 U.S.C. § 271(e)(2).

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed ANDA product. The certification permits the patent owner to sue before commercial launch. A timely suit generally creates a statutory stay of FDA approval for up to 30 months, subject to court rulings and statutory exceptions.

The case was therefore a conventional ANDA action, not a biosimilar case under the Biologics Price Competition and Innovation Act.

What was the district court’s ruling?

The District of New Jersey held the asserted claims of the ’729 patent invalid for obviousness under 35 U.S.C. § 103.

The court evaluated:

1. The scope and content of the prior art.
2. Differences between the prior art and the asserted claims.
3. The level of ordinary skill in the art.
4. The motivation to combine or pursue the relevant teachings.
5. Objective indicia, including alleged unexpected results and clinical success.

The court found that the prior art provided sufficient direction to pursue pirfenidone as a treatment for IPF. Genentech did not establish that the claimed treatment involved an unexpected result sufficient to overcome the obviousness case.

The ruling eliminated the enforceable patent basis for blocking Sandoz’s ANDA product.

What did the Federal Circuit decide in 2022?

The Federal Circuit affirmed the district court’s judgment in Genentech, Inc. v. Sandoz Inc., 55 F.4th 1368 (Fed. Cir. 2022).

The appellate court agreed that the asserted claims were obvious. Its analysis rejected Genentech’s arguments that the prior art failed to provide an adequate motivation to pursue pirfenidone for IPF and that the clinical evidence demonstrated unexpected efficacy.

The Federal Circuit’s decision was important for three reasons:

• It left the asserted claims invalid.
• It confirmed that a method-of-treatment patent can be defeated by prior-art disclosures that identify the compound, the disease, and a rational path to clinical testing.
• It prevented Genentech from using the ’729 patent to delay generic pirfenidone entry.

The Federal Circuit did not create a new rule that all clinical-treatment patents are vulnerable. Its decision turned on the factual record, including the prior art and the evidence concerning pirfenidone’s proposed use in IPF.

Was the asserted patent invalidated or merely found noninfringed?

The outcome was invalidity for obviousness, not a finding that Sandoz’s ANDA product avoided infringement.

That distinction matters commercially. A noninfringement ruling can leave the patent intact and preserve enforcement value against other products. An invalidity ruling removes the patent as a practical barrier, subject to appeal and any separate unasserted patents.

Here, the Federal Circuit affirmed invalidity. Genentech therefore could not rely on the ’729 patent to prevent Sandoz from obtaining approval or marketing a product that practiced the claimed pirfenidone treatment method.

Did the case involve a Paragraph IV challenge?

Yes. Sandoz’s ANDA filing included a Paragraph IV certification against Genentech’s listed patent rights for Esbriet. Genentech responded with an infringement action under the Hatch-Waxman framework.

The case illustrates the commercial function of Paragraph IV litigation:

• Sandoz could challenge the patent before launch.
• Genentech could seek a court judgment before generic approval.
• The litigation created a potential approval delay.
• The generic applicant gained an opportunity to clear the patent estate through invalidity or noninfringement.

The Federal Circuit’s 2022 affirmance resolved the central patent challenge in Sandoz’s favor.

What was the FDA and Orange Book status of Esbriet?

Esbriet was approved under NDA 205832. FDA listed patent information for Esbriet in the Orange Book, including method-of-use protection associated with pirfenidone treatment.

The relevant regulatory structure was:

Regulatory issue	Status
Product type	Small-molecule drug
FDA pathway	NDA for Esbriet; ANDA for Sandoz
Biosimilar pathway	Not applicable
Orange Book listing	Yes
Paragraph IV litigation	Yes
Automatic 30-month stay	Potentially applicable under Hatch-Waxman
Core patent outcome	Asserted patent held invalid for obviousness
FDA approval risk after appellate decision	Reduced substantially

The Orange Book listing did not guarantee that the patent would survive litigation. A listed patent can be challenged through Paragraph IV certification, and a final invalidity judgment can remove its practical blocking effect.

What formulation patents protected Esbriet?

The Genentech-Sandoz case principally concerned the method-of-use patent identified above. Esbriet’s broader patent estate also included formulation, dosage, and method-of-treatment rights.

The patent strategy for pirfenidone has generally involved several layers:

Method-of-use patents

These cover treating IPF or other fibrotic diseases with pirfenidone. The ’729 patent was the central patent in the Sandoz action.

Formulation and dosage patents

These may cover particular tablet or capsule compositions, dosage strengths, release profiles, or administration schedules. Such patents can create separate litigation risks even when a core method patent is invalidated.

Manufacturing and process rights

Process patents can protect synthesis, purification, crystallization, particle characteristics, or production controls. They are less likely than Orange Book-listed method patents to block an ANDA directly, but they can affect supply economics and contract-manufacturing options.

The existence of additional Esbriet-related patents did not preserve the ’729 patent after the Federal Circuit affirmed its invalidity. Each patent would require separate analysis based on its claims, listing status, expiration, and relevance to Sandoz’s proposed product.

When does Esbriet lose exclusivity?

Esbriet’s regulatory exclusivity and patent exclusivity are separate.

FDA approved Esbriet in 2014. New chemical entity exclusivity for the product would have expired in 2019. That exclusivity period did not prevent a Paragraph IV challenge after the first four years, although FDA approval timing remained subject to other listed patents and statutory protections.

The relevant exclusivity sequence was:

Milestone	Date or period
Esbriet FDA approval	October 15, 2014
Five-year NCE exclusivity	Generally through October 2019
Sandoz litigation filed	November 2017
District court invalidity ruling	Before Federal Circuit appeal
Federal Circuit affirmance	December 2022
Generic entry posture	Patent barrier materially weakened after affirmance

Patent expiry depends on the specific patent and patent-term adjustment. The invalidation of the ’729 patent was more significant than its nominal expiration date because it removed the patent before the end of its potential statutory term.

Did the litigation involve biosimilar risk?

No. Pirfenidone is a chemically synthesized small molecule. Sandoz proceeded through the ANDA pathway, not the biosimilar pathway.

The relevant competitive risks were generic substitution and Paragraph IV entry, not biosimilar interchangeability, reference-product exclusivity, or BPCIA patent-exchange procedures.

Sandoz does have a substantial biosimilar business, including products involving monoclonal antibodies and other biologics. That corporate profile does not change the legal character of the Esbriet case.

Which companies challenged Esbriet patents?

Genentech faced multiple generic challenges to Esbriet-related patent rights. The competitive field included Sandoz and other ANDA applicants seeking approval for pirfenidone products.

The principal commercial consequences were:

• Potential approval of lower-priced generic pirfenidone.
• Substitution pressure on Esbriet prescriptions.
• Erosion of Genentech’s branded IPF revenue.
• Reduced value of the invalidated method patent in licensing or settlement negotiations.
• Greater importance of any remaining formulation or use patents.

The case did not produce a biosimilar-style exclusive launch arrangement. The economic model was generic entry after patent clearance.

What revenue exposure did Genentech face?

Esbriet was a meaningful Genentech and Roche product, although its revenue was smaller than products such as Avastin, Herceptin, Rituxan, Perjeta, or Tecentriq.

Roche reported approximately CHF 1.3 billion in Esbriet sales in 2020, with sales affected by competition in the IPF market and later generic-entry pressure. [2] The invalidity judgment increased the risk that pirfenidone revenue would move rapidly from the branded product to generic manufacturers.

Revenue exposure depended on:

• The timing of FDA approval for Sandoz and other ANDA applicants.
• Whether generic products were launched at risk.
• The number of approved generic suppliers.
• Payer substitution and formulary positioning.
• Any surviving Orange Book-listed patents.
• Physician and patient persistence with branded Esbriet.

A method patent that covers the indicated use can have high commercial value because an ANDA applicant may be unable to carve out the protected indication without limiting the product’s market. Once that patent was invalidated, the use-related barrier was substantially reduced.

How strong was Genentech’s Esbriet patent estate after the decision?

The estate became materially weaker, but the decision did not automatically invalidate every Esbriet-related patent.

Strengths before the decision

Before final judgment, the ’729 patent had meaningful leverage because:

• It covered the principal IPF use.
• It was listed in the Orange Book.
• It supported a Hatch-Waxman litigation stay.
• It could delay generic approval if upheld.
• It potentially restricted a carve-out strategy.

Weaknesses exposed by the decision

The Federal Circuit ruling showed that:

• The asserted claims were vulnerable to an obviousness attack.
• Clinical uncertainty did not necessarily establish nonobviousness.
• Commercial success could not overcome the prior-art record without a sufficient nexus and persuasive evidence.
• A method-of-use patent may not survive where the prior art identifies a plausible compound-disease application.

Remaining risk

Genentech could still rely on uninvalidated patents, if any remained relevant to the specific Sandoz formulation, dosage, or manufacturing process. Those rights would need separate claim-level review. The Federal Circuit’s decision did not grant a blanket license to manufacture every possible pirfenidone formulation.

Were there licensing deals or settlement agreements?

The reported appellate disposition was a judgment affirming invalidity, not a settlement-based resolution. The public decision does not establish a licensing agreement between Genentech and Sandoz that preserved the ’729 patent.

A settlement would have required separate analysis of launch timing, licenses, authorized-generic terms, or restrictions on Sandoz’s marketing. The reported Federal Circuit judgment is the operative public outcome for the asserted patent.

What generic launch scenarios resulted from the ruling?

Three commercial scenarios were available after the Federal Circuit affirmance:

1. Immediate or near-term launch after FDA approval. Sandoz could commercialize once regulatory approval and any other applicable patent barriers were cleared.

2. Launch subject to residual patent risk. Sandoz could launch while monitoring other Esbriet patents or related litigation.

3. Delayed launch despite invalidity. Commercial entry could still be delayed by regulatory deficiencies, manufacturing readiness, supply arrangements, or separate patent rights.

The ruling made a launch-at-risk strategy more viable because Genentech’s principal asserted patent could no longer support an injunction.

What is the current litigation status?

The core litigation was resolved against Genentech on appeal. The Federal Circuit affirmed the invalidity judgment in 2022. The case therefore does not present an active, unresolved dispute over the validity of U.S. Patent No. 7,566,729.

The remaining business question is product-specific: whether other patents, regulatory requirements, or commercial arrangements affected Sandoz’s actual launch timing.

Key Takeaways

• The case concerned Sandoz’s ANDA for generic pirfenidone, not a biosimilar.
• Genentech asserted U.S. Patent No. 7,566,729 against Sandoz.
• The district court held the asserted claims obvious.
• The Federal Circuit affirmed in 55 F.4th 1368 (Fed. Cir. 2022).
• The ruling removed the ’729 patent as a blocking patent for Sandoz’s proposed generic treatment.
• Esbriet’s five-year NCE exclusivity had already expired before the appellate decision.
• Any remaining formulation, dosage, manufacturing, or method patents required separate analysis.
• The decision increased generic-entry and revenue-erosion risk for Genentech’s pirfenidone franchise.
• The action was governed by Hatch-Waxman Paragraph IV procedures, not the BPCIA.
• The public appellate record does not identify a settlement license preserving the asserted patent.

FAQs

What was Genentech’s Esbriet patent in the Sandoz case?

The principal asserted patent was U.S. Patent No. 7,566,729, covering methods of treating idiopathic pulmonary fibrosis with pirfenidone.

Did Sandoz win the Genentech pirfenidone lawsuit?

Yes. Sandoz prevailed on the central patent issue after the district court found the asserted claims obvious and the Federal Circuit affirmed.

Was Esbriet’s active ingredient protected by a compound patent?

The litigation focused on a method-of-treatment patent rather than a patent claiming pirfenidone as a new chemical entity.

Could Genentech sue Sandoz again over another Esbriet patent?

Yes. Invalidation of the ’729 patent would not automatically invalidate separate patents directed to formulations, dosages, manufacturing processes, or other methods of use.

Did the case determine whether generic pirfenidone was FDA-approved?

No. The court decided patent issues. FDA approval remained a separate regulatory determination based on Sandoz’s ANDA and FDA’s review.

References

1. U.S. Food and Drug Administration. (2014). FDA approves new treatment for idiopathic pulmonary fibrosis. https://www.fda.gov
2. Roche Holding AG. (2021). Annual report 2020. https://www.roche.com
3. Genentech, Inc. v. Sandoz Inc., No. 1:17-cv-13507, U.S. District Court for the District of New Jersey.
4. Genentech, Inc. v. Sandoz Inc., 55 F.4th 1368 (Fed. Cir. 2022).
5. U.S. Patent No. 7,566,729. Methods of treating idiopathic pulmonary fibrosis. U.S. Patent and Trademark Office.